Cadrenal Therapeutics appoints new chief medical officer
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a biopharmaceutical company specializing in cardiovascular therapies with a market capitalization of $35.2 million and impressive 210% ...
Le Lézard2h
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K ...
pharmaphorum3h
BMS extends its cost-cutting drive by another $2bn
BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...